The outcome of patients with acute lymphoblastic leukemia (ALL) receiving therapeutic donor lymphocyte infusions (DLIs) in relapse after stem cell transplantation (SCT) is poor. We analyzed the impact of prophylactic DLIs in ALL on chimerism and sustained complete remission (CR). Eighty-five patients with ALL were allografted between January 1998 and September 2004. Twenty-six of them received prophylactic DLIs and were included in this analysis. A total of 12 of 13 patients, who were treated with mixed chimerism (MC) converted to complete donor chimerism (92%) and 10 of 12 patients had persistent donor chimerism and sustained CR during subsequent follow-up. Overall, 18 of 26 patients developed graft-versus-host disease (GVHD) after DLIs (69%), acute GVHD in 46 and chronic GVHD in 62%. After a median follow-up of 42 months (14-72) after SCT, 18 of 26 patients (70%) are alive, 16 in CR. Probability of event-free survival (EFS) for patients treated with DLIs is 62%, and overall survival is 70% at 3 years. Our preliminary data support a graft-versus-leukemia effect of prophylactic DLIs able to induce stable donor chimerism and ongoing CR after SCT. As the accompanying GVHD rate was considerable, careful selection of patients for prophylactic DLIs is mandatory.
Introduction
Patients with high-risk acute lymphoblastic leukemia (ALL) (Ph þ , t(4;11), B-lineage high white blood cells (WBC) and/or complete remission (CR) 44 weeks, early and mature T-ALL) are candidates for allogeneic hematopoietic stem cell transplantation (SCT) in CR-1. 1 SCT shows a strong graft-versus-leukemia (GVL) effect in ALL, but relapse rates in subgroups of ALL are considerable and increase with advanced disease. [1] [2] [3] [4] Therefore, innovative post transplant strategies are urgently needed to reduce the relapse risk in these patients.
A strong GVL effect of donor lymphocyte infusions (DLIs) has been observed in relapsed chronic myeloid leukemia (CML) after allogeneic SCT, where DLIs induce a high rate of stable CR. 5, 6 Patients with relapsed CML, who achieve molecular remission after DLIs have a 3-yearsurvival probability of 95%. 7 Conversely, patients with a high tumor burden and fast growth kinetics as in relapsed acute leukemias and blast crises of CML show poor response rates to DLIs and a short overall survival (OS) despite the fact that there are examples of successful treatment of relapsed ALL. 5, 6, [8] [9] [10] The optimal timing, interval and the cell dose of DLIs to ensure a GVL effect with low toxicity is unknown, because DLIs are frequently followed by graft-versus-host disease (GVHD) and myelosuppression. Known factors influencing the incidence of GVHD are initial and cumulative T-cell dose and time between transplantation and the first DLI administration. 5, 11, 12 Compared to a singledose infusion, escalating doses administered over several months considerably lower the incidence of GVHD and therapy-related mortality (TRM) while retaining the antileukemic effect of DLIs. 11, 13 Experience with DLIs has increased considerably over recent years, together with the development of reduced intensity conditioning (RIC) regimens. These are frequently followed by prolonged periods of mixed chimerism (MC). 14 Several studies have shown that persistent MC results in an increased relapse risk in various hematologic malignancies. [14] [15] [16] DLIs were shown to convert MC to complete donor chimerism (CC) in several malignancies after SCT. 17, 18 To date, few patients with relapsed ALL have received DLIs, with very limited success so far, because of the rapid disease kinetics of relapsed ALL and the fact that ALL patients mostly undergo standard high-dose conditioning with rapid and complete donor cell engraftment. A retrospective analysis of a larger series of patients with relapsed ALL has shown limited effects of DLIs in single patients, with almost no impact on the further course of disease in most patients. 19 Even fewer ALL patients have been treated with prophylactic DLIs. In a small group of children with ALL, DLIs seemed to prevent relapse in patients with MC after SCT. 20 Our own data suggested that the conversion of MC to CC after RIC by DLIs was a prerequisite for stable CR in patients with ALL and AML. 17 Based on these observations and the high relapse rates in high-risk ALL after SCT we initiated a pilot study to evaluate the effect of prophylactic DLIs to patients with high-risk ALL to prevent hematologic relapse. Administration of DLIs, toxicity and outcome of these patients will be presented.
Patients and methods
A total of 85 adult patients with ALL underwent allogeneic SCT between January 1998 and September 2004. Allogeneic SCT were performed from HLA-identical (6 of 6) related or unrelated donors in 80 of 85 patients; 5 of 85 patients were transplanted from mismatch donors (class I mismatch: n ¼ 3, class II mismatch: n ¼ 2). Among these 85 patients 26 patients received prophylactic DLIs.
All patients were transplanted according to the German Multicenter Study Group for Adult ALL protocols (GM-ALL). Indications for allogeneic SCT were Ph þ ALL, translocation t(4;11), B-lineage ALL with WBC 430 per nl, CR-1 44 weeks induction therapy, early and mature T-ALL in CR-1, relapsed or refractory ALL. Patients received either a myeloablative (high dose) conditioning regimen with 6 Â 2 Gy TBI and 2 Â 60 mg/kg cyclophosphamide and/or 60 mg/kg VP16 or a RIC regimen with 6 Â 30 mg/m 2 fludarabine, 2 Â 4 mg/kg busulfan and 4 Â 10 mg/kg antithymocyte globulin (Fresenius, Bad Homburg, Germany). 1 A total of 69 patients received granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood cells, whereas 16 patients received bone marrow grafts. Postgraft immunosuppression was administrated according to the GM-ALL studies and comprised cyclosporine A (CSA), prednisone and/or methotrexate (MTX). CSA and mycophenolate mofetil were given to patients after RIC. 1 Patient characteristics are summarized in Table 1 .
DLIs administration was planned according to the GM-ALL. All patients were planned to receive DLIs under the following conditions: no active infection, no leukemic relapse, no history of severe acute or chronic GVHD before DLIs, no active GVHD at the time of planned DLIs, no patient refusal.
The study protocols were approved by the institutional review board, and written informed consent was obtained from all patients.
DLIs were planned to commence no earlier than day 60 after SCT and given in escalating doses every 4 weeks, starting with 1.0 Â 10 7 for related and 0.5 Â 10 7 CD3 þ cells per kg for unrelated donors. Chimerism analysis from peripheral blood was performed at days 30, 60, 90 and then at 4-to 8-week intervals for 1 year at least. Bone marrow samples were analyzed 1, 3, 6 and 12 months after SCT. Analyses were performed from leukocyte subpopulations using a multiplex PCR of polymorphic short tandem repeats. 21, 22 MC was defined as 5% or more recipient cells in at least one leukocyte subpopulation in two independent analyses after hematopoietic reconstitution. 17 All patients were in hematological, cytogenetic and molecular CR at the time of first DLIs.
Acute and chronic GVHD were graded as previously described.
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Donor lymphocyte infusions A total of 26 of 85 patients received prophylactic DLI. Fifty-nine patients did not receive prophylactic DLI because of early relapse (16 patients), severe acute GVHD grade IV (13 patients), chronic extensive GVHD (17 patients), nonavailability of DLI (6 patients), early TRM (4 patients) and short follow-up (3 patients). Further analyses were confined to the 26 patients receiving DLI, as this was meant to be a pilot study rather than a randomized study.
In these 26 patients, the median age was 30 years (range, 18-47 years), with 18 males and 8 females. Further patient characteristics are shown in Table 2 . Patients transplanted from an unrelated donor received DLI from a G-CSFmobilized peripheral blood cell graft (n ¼ 8) and those transplanted from a sibling donor received nonmobilized donor lymphocytes (n ¼ 18).
Statistical analysis
Statistical analysis was performed using SPSS 12.0 for Windows. Results are given with median and range. The exact w
2
-test was used to compare different subgroups. Survival data were analyzed according to Kaplan-Meier and tested univariately with log-rank test. 25 Significance was assessed at the Po0.05 level, two sided.
Results
The first DLI were given at a median of 112 days after SCT (range, 29-324 days). First DLI was delayed in 16 of 26 patients because of acute GVHD, poor general status or ongoing immunosuppression. One patient received DLI on day 29 because he had around 5% blasts on bone marrow cytology on day 28 and early relapse was suspected. The patient remained in CR thereafter.
Patients received a median of two DLI (range, 1-4). The median cumulative cell dose given was 3.75 Â 10 7 CD3 þ cells per kg (range, 0.1-16.5).
Chimerism after donor lymphocyte infusions
Chimerism data were available for all patients before DLI. A total of 14 patients received DLI with persistent MC, and 12 patients received DLI with CC. After DLI in MC, the donor-recipient profile converted to CC in 12 of 13 patients (92%) analyzed. The one patient who did not convert to CC relapsed and died of leukemia. Of the 12 converted patients, 10 (83%) remained in CC and CR, 2 eventually died of relapse.
A total of 10 of 12 patients who received DLI with CC had persistent full donor chimerism and CR in subsequent assessments (83%); 2 of 12 patients (17%) developed MC, 1 of them finally relapsed and the other reverted to stable CC on the subsequent follow-up.
Toxicity after donor lymphocyte infusions
A total of 18 of 26 patients (69%) developed acute and/or chronic GVHD after DLI administration. The incidence of acute GVHD grades I-IV was 46% (n ¼ 12). Seven patients (26%) developed acute GVHD grade I, two patients (8%) developed acute GVHD grade II and three patients (12%) developed severe acute GVHD grades III-IV. Chronic GVHD occurred in 16 of 26 patients (62%). Three of 16 had limited and 13 of 16 had extensive chronic GVHD. There was no significant difference in GVHD incidence in patients receiving DLI from a G-CSF-mobilized peripheral blood cell graft or nonmobilized donor lymphocytes (data not shown).
Among the 10 patients receiving one dose of DLI, acute GVHD occurred in 9 patients, chronic GVHD in 7 patients, and acute and chronic GVHD in 7 patients.
Among the eight patients receiving two doses of DLI, acute GVHD developed in three patients, chronic GVHD in six patients, and acute and chronic GVHD in three patients.
Among the six patients receiving three DLI administrations, three patients developed chronic GVHD. Neither of the two patients receiving four DLI doses developed GVHD after DLI.
The rate of GVHD differed between patients receiving DLI with MC and those with CC (Po0.05). Acute and/or chronic GVHD was seen in 12 of 14 patients (86%) receiving DLI with MC (acute GVHD in 9, chronic GVHD in 11, and acute and chronic GVHD in 8 patients). A total of 12 patients received prophylactic DLI in CC and GVHD developed in 6 of them (50%) (acute GVHD in three, chronic GVHD in five patients, and acute and chronic GVHD in two patients) (Figure 1) . None of the patients developed bone marrow aplasia after DLI.
Outcome A total of 8 of 26 patients (30%), who had received DLI have died. Three of eight patients died due to infections and GVHD after DLI (TRM 11%); one patient died from a myocardial infarct, which was not attributed to the use of DLI. Four of eight patients died because of leukemia relapse (15% overall) ( Table 2 ). A total of 18 patients Figure 2 ) and 70% for OS with a mean survival of 53 months (95% CI, 43-64 months) after SCT. There was no significant difference in the outcome of patients receiving DLI from a G-CSF-mobilized peripheral blood cell graft or nonmobilized donor lymphocytes. A total of 37 of 59 patients who had not received prophylactic DLI have died (63%). Among these 59 patients, 4 received therapeutic DLI in relapse. All four died from refractory disease 1-7 months after DLI. 20 of 59 patients died due to disease relapse (34%). 17 patients (29%) died of transplant-related causes, mainly due to infections and GVHD. 22 patients (37%) are alive and in CR. Median follow-up is 19 months (3-78) after SCT (Figure 3 ).
Discussion
The rationale for administering prophylactic DLI before clinical and hematological relapse lies in the wellknown rapid disease kinetics of relapsed ALL and the known minor effect of immunological treatment strategies in these patients. 5 DLI are capable of converting MC into full donor chimerism and have demonstrated a strong GVL effect in various relapsed malignancies, with high conversion rates from MC to full donor chimerism. 5, 17, 18, [26] [27] [28] The effect of DLI on relapsed ALL has rarely been investigated and has proven mostly unsuccessful despite the fact that the first patient treated with DLI was a patient with ALL. 10 A total of 44 patients with relapsed ALL after SCT from 27 centers were retrospectively analyzed; only 15 received DLI without prior chemotherapy and 2 of 15 patients entered remission. 19 Other studies have included few, or no patients with ALL. Four of six patients with relapsed ALL attained CR after administration of DLI. 9, 10 Seven ALL patients were among 58 patients with relapse after allogeneic SCT, 3 of 7 received chemotherapy before DLI and 2 of 4 evaluable patients with ALL achieved CR. 8 In a retrospective analysis of 140 allograft patients, who received therapeutic DLI after relapse, 11 ALL patients were included. Only 2 of 11 ALL patients achieved a CR. 6 In another study of 46 patients receiving DLI, none had ALL. 28 The role of prophylactic DLI in acute leukemia was first described in a group of patients receiving DLI after allogeneic SCT with a T-cell-depleted graft. 29 This strategy differed from our study as our patients did not receive T-cell-depleted stem cell grafts.
In a small group of 12 transplanted children with acute leukemia and myelodysplastic syndromes, the withdrawal of immunosuppression followed by DLI administration was capable of preventing relapse in a high-risk situation, with increasing host chimerism. 20 This was regarded as an indication of antileukemic effect of prophylactic DLI in these patients.
Although only 26 patients were finally included in our pilot study, this is the largest series of patients with ALL receiving prophylactic DLI after allogeneic SCT. Considering the fact that only 26 of 85 patients finally received DLI, it is obvious that these patients represent a selected group with better performance status, no GVHD before DLI and no early relapse after SCT. A comparative analysis is therefore impossible.
Nevertheless, our data demonstrate the ability of DLI to convert MC to stable CC. Most patients with sustained CC had ongoing CR.
Patients had received identical pretransplant chemotherapy according to the GM-ALL protocols.
1 Almost all patients (24 of 26 patients) had been transplanted after standard high-dose conditioning with chemoradiotherapy. Most recent studies on DLI have been performed after RIC because of the high rate of MC observed after RIC. 17, 18, 28, 30 Patients receiving DLI for persistent MC had a high rate of chimerism conversion (92%). Those who remained in CC had a very high rate of continuous CR (83%), suggestive of a GVL effect of DLI. A GVL effect of allogeneic SCT in ALL can be concluded from large clinical Prophylactic DLI in adult ALL C Lutz et al series also demonstrating the antileukemic effect of mild GVHD. [2] [3] [4] After DLI, patients had very favorable survival rates with 3-year probabilities of 70% for OS and 62% for EFS. A direct comparison between patients with and without DLI is tempting, but the many confounding variables were not balanced between groups. However, the relation of patients in CR-1 versus patients beyond CR-1 was equally distributed, which was 46 versus 54% in the DLI patients and 44 versus 56% in patients not receiving prophylactic DLI. More patients without DLI received bone marrow as the stem cell source, while the majority of DLI patients were transplanted with peripheral blood stem cells. Selection of the patients for DLI was obvious in many cases, and the superior survival rates after DLI therefore reflect patient selection, precluding comparative statistical analysis.
The toxicity of DLI was high in our series of patients. A total of 18 patients developed acute and/or chronic GVHD. No consensus has been reached to date for classifying GVHD after DLI. Although GVHD frequently presents as an acute illness after DLI, with a high rate of gut involvement, the onset is mostly beyond day 100 after allogeneic SCT, which defines chronic GVHD. 24 We classified GVHD as acute if it developed before day 100 after the first DLI, and chronic if it developed afterwards, because donor T-lymphocytes, which were infused in high numbers with DLI are regarded as major effectors of GVH-and GVL reaction. 31 A higher rate of GVHD was observed after DLI in MC, although numbers in both groups are small (14 versus 12 patients). Nevertheless, these clinical results are in line with experimental data, showing that the interaction of donor T-lymphocytes with antigen-presenting recipient cells is crucial for the development of acute GVHD. 32 In canine studies, MC was a prerequisite for a DLI-mediated GVL effect. 33 The GVHD rate was higher than in other studies. 18, 28 However, in these studies DLI were given in clinical relapse with a high number of malignant recipient cells present limiting the immunologic efficacy of donor cells. We only included patients in our study with no clinical and hematologic relapse, thereby excluding high numbers of malignant cells being present. Several of our patients had just stopped the immunosuppressive therapy before starting DLI and some were still receiving small doses of CSA or prednisone. We feel that the almost concomitant withdrawal of immunosuppression and use of DLI in several patients contributed to the high rate of GVHD and should be avoided. We postponed the first infusion of DLI in more recent patients until all immunosuppression was finished. The early administration of the first DLI is also likely to have contributed to the high rate of GVHD, although only 9 of 26 patients received DLI at the planned time point due to GVHD or ongoing immunosuppression.
Although chronic GVHD reduces the relapse risk and ensures long-term CRs, severe acute and chronic GVHD still are major contributors to transplant-related morbidity and mortality after allogeneic SCT. 34, 35 Because of the high GVHD incidence in our study, we withheld DLI in all patients beyond day 100 and after termination of immunosuppression reduced the starting dose to 0.1 Â 10 7 CD3 þ cells per kg in order to reduce GVHD incidence in the future.
Limitations of this study are its uncontrolled nature, which has resulted in the positive selection of patients in CR without GVHD being considered eligible for DLI. A direct comparison with those 59 SCT patients, who did not receive DLI is therefore not possible. Whether G-CSF mobilized or unmobilized CD3 þ lymphocytes are preferable as donor lymphocytes is unknown and this is often determined by availability. In our study, we saw no significant differences in the outcome of patients receiving DLI from a G-CSF-mobilized peripheral blood cell graft or nonmobilized donor lymphocytes.
In conclusion, our pilot study shows that prophylactic DLI are feasible in high-risk and very high-risk ALL after allogeneic SCT. Our data suggest a GVL effect induced by DLI in these patients, as shown by the high chimerism conversion rate. The high rate of GVHD after DLI calls for careful selection of patients with a high relapse risk, sufficient time between the withdrawal of immunosuppression and use of the first DLI and longer intervals between infusions of donor lymphocytes. In the near future, ex vivo manipulation of donor lymphocytes through CD8 depletion, activation with CD3/CD28 costimulation or the transfer of leukemia-reactive specific T-cell clones might enhance a GVL effect and reduce the GVHD risk. [36] [37] [38] Selection of eligible patients remains an issue to date unresolved. The impact of DLI on eradication of ALL after allogeneic SCT can only be proven in prospective randomized studies including analyses of chimerism and minimal residual disease status.
